10:37 AM EST, 11/24/2025 (MT Newswires) -- Gelteq ( GELS ) shares rose 26% in recent Monday trading after the company reported positive preclinical results for its gel-based drug delivery platform.

In a comparative pharmacokinetic study, Gelteq ( GELS ) said its formulation improved absorption and systemic exposure by 38% to 45% compared with a marketed antihistamine. The gel also delivered higher peak concentrations while maintaining a similar time to peak plasma levels, the company said Monday in a statement.

The results offer "opportunities well beyond the antihistamine market, and into much larger drug categories where improved absorption, ease of administration, and patient-friendly formats can create immediate value," Gelteq ( GELS ) Chief Executive Officer Nathan Givoni said in the statement.

The company plans to pursue a US Food and Drug Administration approval pathway for an antihistamine product using the platform.

Price: 1.11, Change: +0.23, Percent Change: +26.06